A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
Phase 2
Recruiting
- Conditions
- SchizophreniaCognitive Impairment Associated With Schizophrenia (CIAS)Cognitive Impairment
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Recognify Life Sciences
- Target Recruit Count
- 234
- Registration Number
- NCT05686239
- Locations
- 🇵🇱
Recognify Research Site, Gdansk, Poland
🇺🇸Collaborative Neuroscience Research, Garden Grove, California, United States
Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia
Phase 2
Completed
- Conditions
- Cognitive ImpairmentSchizophrenia
- Interventions
- Drug: RL-007 Matching Placebo
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Recognify Life Sciences
- Target Recruit Count
- 37
- Registration Number
- NCT04822883
- Locations
- 🇺🇸
Collaborative Neuroscience Research, Long Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath